TARS
TarsusDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-11
Current thesis
Bull case assumes strong clinical readouts, faster-than-expected commercial uptake, and multiple expansion driven by durable reimbursement; market re-rates to ~+25% above anchor.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -9.8.
What can break
Late-stage clinical failure or trial delay
Momentum
20
Value
41
Sentiment
81
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $87.87 · Bull $99.85 · Bear $55.92
Data freshness
Prices
As of 2026-06-11
Fundamentals
As of 2026-06-10 • Vendor: Data Vendor v1
Scores
As of 2026-06-11 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-07 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-11
Investment thesis
As of 2026-06-11
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $94.22
Why
Momentum20 · Δ7d -4.2
Value41 · Δ7d -0.1
Sentiment81 · Δ7d -9.8
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
20
34% active weight
Current posture
7d trendSoftening
Δ7d
-4.2
Δ21d
-6.1
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.1
Sentiment
81
33% active weight
Current posture
7d trendSoftening
Δ7d
-9.8
Δ21d
+6.1
Why this grade
Composite grade D. Momentum 19.8 / Value 41.0 / Sentiment 80.7
Fundamentals (TTM)As of 2026-06-10
Fundamentals (TTM)
As of 2026-06-10
Market Cap
$2.64B
Beta
0.58
Shares Out
42.45M
P/E (TTM) · Derived
-39.1
P/S (TTM)
9.25
P/FCF (TTM) · Derived
-40.43
Rev YoY
+146.7%
EPS YoY
+51.6%
Gross Margin
+93.3%
Op Margin
-23.9%
Net Debt
-$219.53M
Current Ratio
4.29
As of 2026-06-11 • Updated nightlySource: Internal modelMethodology